The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
Open accessAbstract
Mutations or aberrant upregulation of EZH2 occur frequently in human cancers, yet clinical benefits of EZH2 inhibitor (EZH2i) remain unsatisfactory and limited to certain hematological malignancies. We profile global posttranslational histone modification changes across a large panel of cancer cell lines with various sensitivities to EZH2i. We report here oncogenic transcriptional reprogramming mediated by MLL1's interaction with the p300/CBP complex, which directs H3K27me loss to reciprocal H3K27ac gain and restricts EZH2i response. Concurrent inhibition of H3K27me and H3K27ac results in transcriptional repression and MAPK pathway dependency in cancer subsets. In preclinical models encompassing a broad spectrum of EZH2-aberrant solid tumors, a combination of EZH2 and BRD4 inhibitors, or a triple-combination including MAPK inhibition display robust efficacy with very tolerable toxicity. Our results suggest an attractive precision treatment strategy for EZH2-aberrant tumors on the basis of tumor-intrinsic MLL1 expression and concurrent inhibition of epigenetic crosstalk and feedback MAPK activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citationEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Proteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Extraction, purification and analysis of histones
Shechter, D., Dormann, H. L., Allis, C. D., & Hake, S. B. (2007) · Nature Protocols · doi:10.1038/nprot.2007.202 · Cited by 1,064
Transcriptional regulation by Polycomb group proteins
Di Croce, L., & Helin, K. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2669 · Cited by 864
Bachmann, I. M., Halvorsen, O. J., Collett, K., Stefansson, I. M., Straume, O., Haukaas, S. A., Salvesen, H. B., Otte, A. P., & Akslen, L. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5180 · Cited by 851
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., Schultz, D. C., Liu, Q., Shih, I.-M., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 678
Lee, W., Teckie, S., Wiesner, T., Ran, L., Prieto Granada, C. N., Lin, M., Zhu, S., Cao, Z., Liang, Y., Sboner, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3095 · Cited by 619
Self-citationLysine succinylation and lysine malonylation in histones
Xie, Z., Dai, J., Dai, L., Tan, M., Cheng, Z., Wu, Y., Boeke, J. D., & Zhao, Y. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.015875 · Cited by 613
Self-citationPolycomb-Dependent H3K27me1 and H3K27me2 Regulate Active Transcription and Enhancer Fidelity
Ferrari, K. J., Scelfo, A., Jammula, S., Cuomo, A., Barozzi, I., Stützer, A., Fischle, W., Bonaldi, T., & Pasini, D. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.10.030 · Cited by 512
β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis
Monga, S. P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.056 · Cited by 487
McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116418109 · Cited by 483
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., Helin, K., Hornick, J. L., Mautner, V., Kehrer-Sawatzki, H., et al. (2014) · Nature · doi:10.1038/nature13561 · Cited by 461
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kim, K. H., Kim, W., Howard, T. P., Vazquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3968 · Cited by 406
Pasini, D., Malatesta, M., Jung, H. R., Walfridsson, J., Willer, A., Olsson, L., Skotte, J., Wutz, A., Porse, B., Jensen, O. N., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq244 · Cited by 401
Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Nagaraja, S., Vitanza, N. A., Woo, P. J., Taylor, K. R., Liu, F., Zhang, L., Li, M., Meng, W., Ponnuswami, A., Sun, W., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.011 · Cited by 396
Loss of BAP1 function leads to EZH2-dependent transformation
LaFave, L. M., Béguelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A., Papalexi, E., Keller, M. D., Hricik, T., Konstantinoff, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3947 · Cited by 381
Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors
Zhang, M., Wang, Y., Jones, S., Sausen, M., McMahon, K., Sharma, R., Wang, Q., Belzberg, A. J., Chaichana, K., Gallia, G. L., et al. (2014) · Nature Genetics · doi:10.1038/ng.3116 · Cited by 301
Self-citationShin, S., Dimitri, C. A., Yoon, S.-O., Dowdle, W., & Blenis, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.020 · Cited by 291
ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?
Buscà, R., Pouysségur, J., & Lenormand, P. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00053 · Cited by 284
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia
Jaffe, J. D., Wang, Y., Chan, H. M., Zhang, J., Huether, R., Kryukov, G. V., Bhang, H.-E. C., Taylor, J. E., Hu, M., Englund, N. P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2777 · Cited by 277
Self-citationEZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
Fillmore, C. M., Xu, C., Desai, P. T., Berry, J. M., Rowbotham, S. P., Lin, Y.-J., Zhang, H., Marquez, V. E., Hammerman, P. S., Wong, K.-K., et al. (2015) · Nature · doi:10.1038/nature14122 · Cited by 255
Wang, S.-P., Tang, Z., Chen, C.-W., Shimada, M., Koche, R. P., Wang, L.-H., Nakadai, T., Chramiec, A., Krivtsov, A. V., Armstrong, S. A., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.028 · Cited by 251
Lefloch, R., Pouysségur, J., & Lenormand, P. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00800-07 · Cited by 206
DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes
Choi, S. H., Gearhart, M. D., Cui, Z., Bosnakovski, D., Kim, M., Schennum, N., & Kyba, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw141 · Cited by 196
Lai, B., Lee, J.-E., Jang, Y., Wang, L., Peng, W., & Ge, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx234 · Cited by 191
Chen, Y., Kwon, S. W., Kim, S. C., & Zhao, Y. (2005) · Journal of Proteome Research · doi:10.1021/pr049754t · Cited by 177
Self-citationBeating the odds: BETs in disease
Wang, C., & Filippakopoulos, P. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.06.002 · Cited by 158
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
Scott, M. T., Korfi, K., Saffrey, P., Hopcroft, L. E. M., Kinstrie, R., Pellicano, F., Guenther, C., Gallipoli, P., Cruz, M. M. A., Dunn, K. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0263 · Cited by 153
Vincenz, C., & Kerppola, T. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805317105 · Cited by 140
Jung, H. R., Pasini, D., Helin, K., & Jensen, O. N. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900489-mcp200 · Cited by 138
Kurmasheva, R. T., Sammons, M. C., Favours, E., Wu, J., Kurmashev, D., Cosmopoulos, K., Keilhack, H., Klaus, C. R., Houghton, P. J., & Smith, M. A. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26218 · Cited by 129
Tie, F., Banerjee, R., Saiakhova, A., Howard, B., Monteith, K. E., Scacheri, P. C., Cosgrove, M. S., & Harte, P. J. (2014) · Development · doi:10.1242/dev.102392 · Cited by 121
The Landscape of Histone Modifications in a High-Fat Diet-Induced Obese (DIO) Mouse Model
Nie, L., Shuai, L., Zhu, M., Liu, P., Xie, Z., Jiang, S., Jiang, H., Li, J., Zhao, Y., Li, J.-Y., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m117.067553 · Cited by 114
Self-citationEZH2 alterations in follicular lymphoma: biological and clinical correlations
Huet, S., Xerri, L., Tesson, B. M., Mareschal, S., Taix, S., Mescam-Mancini, L., Sohier, E., Carrère, M., Lazarovici, J., Casasnovas, O., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.32 · Cited by 102
Frémin, C., Ezan, F., Boisselier, P., Bessard, A., Pagès, G., Pouysségur, J., & Baffet, G. (2007) · Hepatology · doi:10.1002/hep.21551 · Cited by 99
Paulo, J. A., McAllister, F. E., Everley, R. A., Beausoleil, S. A., Banks, A. S., & Gygi, S. P. (2014) · PROTEOMICS · doi:10.1002/pmic.201400154 · Cited by 70
Brach, D., Johnston-Blackwell, D., Drew, A., Lingaraj, T., Motwani, V., Warholic, N. M., Feldman, I., Plescia, C., Smith, J. J., Copeland, R. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0840 · Cited by 70
Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status
Schoumacher, M., Corre, S. L., Houy, A., Mulugeta, E., Stern, M., Roman‐Roman, S., & Margueron, R. (2016) · Nature Medicine · doi:10.1038/nm.4098 · Cited by 67
Paulo, J. A., Gaun, A., & Gygi, S. P. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00398 · Cited by 63
Sun, R., Shen, J. K., Gao, Y., Zhou, Y., Yu, Z., Hornicek, F. J., Kan, Q., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.9518 · Cited by 63
Paulo, J. A., & Gygi, S. P. (2014) · PROTEOMICS · doi:10.1002/pmic.201400155 · Cited by 46
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
EZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 926
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
Chen, Q., Yang, B., Liu, X., Zhang, X. D., Zhang, L., & Liu, T. (2022) · Theranostics · doi:10.7150/thno.73223 · Cited by 261
Self-citationHistone Lysine Methylation Dynamics Control EGFR DNA Copy-Number Amplification
Clarke, T. L., Tang, R., Chakraborty, D., Van Rechem, C., Ji, F., Mishra, S., Ma, A., Kaniskan, H. Ü., Jin, J., Lawrence, M. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0463 · Cited by 50
Metadata
- Authors
- Huang, X., Yan, J., Zhang, M., Wang, Y., Chen, Y., Fu, X., Wei, R., Zheng, X.-L., Liu, Z., Zhang, X., Yang, H., Hao, B., Shen, Y.-Y., Su, Y., Cong, X., Huang, M., Tan, M., Ding, J., & Geng, M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 175
- Issue
- 1
- Pages
- 186-199.e19
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2892042921
- Cited by
- 264
- References
- 49
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.